Dacomitinib is a second-generation TKI that has recently gained FDA-approval for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations.24 This TKI has not previously been reported on in PCa. Here, EGFR is linked to non-small cell lung carcinoma.